跳至主要内容
临床试验/NL-OMON24926
NL-OMON24926已完成不适用

A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves¡¯ Orbitopathy with reduced systemic steroid exposure

Het Oogziekenhuis Rotterdam /Rotterdam Ophthalmic Institute<br>PO Box 70030, NL-3000 LM Rotterdam<br>Telephone: +31 (0) 10 4023 4490 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20

研究概览

简要总结

Paridaens D, Detiger SE, Kremer T, Dalm VASH, de Keizer ROB, Dik WA, Wubbels R, Peeters RP. Nanocort in the medical treatment of moderate-to-severe Graves’ orbitopathy: A pilot study. Acta Ophthalmol. 2020; 98(Suppl. S264): 10. [Abstract] Detiger SE, Kremer TM, Dalm VASH, de Keizer ROB, Wubbels RJ, Metselaar JM, van Hagen PM, Peeters RP, Paridaens D. A pilot study on the use of prednisolone encapsulated liposomes for the treatment of moderate-to-severe Graves’ orbitopathy with reduced systemic steroid exposure. Acta Ophthalmol, 2021; 99: 797-804. PMID: 33423386

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male or female ≥ 18 years old.
  • 2. Informed consent.

排除标准

  • 1. Sight threatening GO due to optic neuropathy (decrease of (pinhole) vision, visual field loss, prolonged VEP, diminished colour vision) or severe keratopathy.
  • 2. Any concurrent illness, disability or clinically significant abnormality that may, as judged by the investigator, affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.

研究者

发起方
Het Oogziekenhuis Rotterdam /Rotterdam Ophthalmic Institute<br>PO Box 70030, NL-3000 LM Rotterdam<br>Telephone: +31 (0) 10 4023 449

相似试验